Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma
- PMID: 29604510
- PMCID: PMC6054590
- DOI: 10.1016/j.tranon.2018.02.021
Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma
Abstract
Multiple myeloma (MM) is a very heterogeneous disease, characterized by multiple cytogenetic aberrations on plasma cells (PC) that have been traditionally used to predict the outcome of the disease. A mayor issue on the analysis of PC is the sometimes low infiltration of these cells in the bone marrow that hampers cytogenetic studies. To solve this problem we have optimized a selection strategy based on PC immunomagnetic isolation that has allowed us to lower to 1% the minimal PC infiltration requirement without loss of purity, enabling to perform genetic analysis. In this study, we have analyzed 153 bone marrow samples of patients suspected of MM, collected from February 2015 to May 2017 by the Genetics service of the Complejo Hospitalario de Navarra. Clinical characteristics of the patients and PC immunophenotyping, conventional cytogenetics and interphase fluorescence in situ hybridization (iFISH) analyses have been assessed on these samples. In our cohort 90% of the samples had cytogenetic abnormalities, among them 50% presented immunoglobulin rearrangements, 41.9% showed 1q gains, 29.7% showed 1p deletions and 33% presented TP53 deletion.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells.Rev Bras Hematol Hemoter. 2016 Apr-Jun;38(2):113-20. doi: 10.1016/j.bjhh.2016.01.005. Epub 2016 Feb 23. Rev Bras Hematol Hemoter. 2016. PMID: 27208569 Free PMC article.
-
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.Ther Adv Med Oncol. 2024 Jan 19;16:17588359231221340. doi: 10.1177/17588359231221340. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38249329 Free PMC article.
-
Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.Cancer. 2003 Feb 1;97(3):601-9. doi: 10.1002/cncr.11100. Cancer. 2003. PMID: 12548602
-
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.Cancer Genet. 2011 Jan;204(1):3-12. doi: 10.1016/j.cancergencyto.2010.11.002. Cancer Genet. 2011. PMID: 21356186 Review.
-
Recent advances in cytogenetic characterization of multiple myeloma.Int J Lab Hematol. 2019 Feb;41(1):5-14. doi: 10.1111/ijlh.12882. Epub 2018 Jul 3. Int J Lab Hematol. 2019. PMID: 29971938 Review.
References
-
- Kyle R.A., Gertz M.A., Witzig T.E., Lust J.A., Lacy M.Q., Dispenzieri A., Fonseca R., Rajkumar S.V., Offord J.R., Larson D.R. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. - PubMed
-
- De Gramont A., Grosbois B., Michaux J.L., Peny A.M., Pollet J.P., Smadja N., Krulik M., Debray J., Bernard J.F., Monconduit M. IgM myeloma: 6 cases and a review of the literature. Rev Med Interne. 1990;11(1):13–18. - PubMed
-
- Dierlamm T, Laack E, Dierlamm J, Fiedler W, Hossfeld DK. IgM myeloma: a report of four cases. Ann Hematol. 2002;81(3):136–139. - PubMed
-
- Pandey S, Kyle RA. Unusual myelomas: a review of IgD and IgE variants. Oncology (Williston Park) 2013;27(8):798–803. - PubMed
-
- Tchinda J., Volpert S., Kropff M., Berdel W.E., Kienast J., Meinhardt F., Horst J. Frequent gains of the short arm of chromosome 9 in multiple myeloma with normal G-banded karyotype detected by comparative genomic hybridization. Am J Clin Pathol. 2004;122(6):875–882. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous